The approval of Biogen’s Alzheimer’s drug has reignited investor interest in a contested hypothesis about what causes the disease, despite years of failures in the field and staunch dismissal of the theory by many scientists and doctors.
百健(Biogen)研发的阿尔茨海默病(Alzheimer)药物获批，重新点燃了投资者对一种关于阿尔茨海默病病因的有争议假说的兴趣，尽管该领域多年来一直失败，许多科学家和医生也坚决否定这一理论。
您已阅读5%（334字），剩余95%（6595字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。